Researchers from North Carolina State University have synthesized an analog of lipoxazolidinone A, a small molecule that is effective against drug-resistant bacteria such as MRSA. This molecule, a new synthetic compound inspired by a natural product, could be a useful chemical tool for studying other Gram-positive infections and may have implications for future drug creation.
Lipoxazolidinone A is a natural product which had been previously isolated from bacteria living in marine sediments. It is a secondary metabolite – a small molecule produced by the bacteria that isn’t key to its survival but is produced for a secondary purpose, like defense. When lipoxazolidinone A was initially isolated, researchers noted that it seemed effective against Gram-positive bacteria, like MRSA.
NC State chemist Joshua Pierce aimed to confirm those original findings and understand how the molecule’s structure correlated to its function; in short, he wanted to recreate the molecule to see what portions were directly responsible for its anti-microbial properties and then potentially improve upon that structure.
Pierce, along with current NC State graduate student Kaylib Robinson and former students Jonathan Mills and Troy Zehnder, used novel chemical tools to synthesize lipoxazolidinone A in the lab. They were able to confirm that its chemical structure matched what the initial researchers had indicated, then they worked to identify the portion of the molecule that was responsible for the activity against Gram-positive bacteria. Their result was a compound with improved potency, JJM-35.
They tested JJM-35 against a panel of resistant and non-resistant bacteria. When tested against MRSA in vitro, they found that the synthesized molecule was up to 50 times more effective than the natural product against several bacterial strains. Additionally, they found that the molecule was often more effective against resistant bacterial strains than it was against nonresistant strains.
“An exciting additional aspect of this work was that we identified that these molecules may function by inhibiting multiple biosynthetic pathways directly or indirectly,” says Pierce. “This means that bacteria may have difficulty developing resistance to potential drugs developed from these molecules.”
While more work is needed, Pierce hopes that JJM-35 and similar compounds can be used as tools to study other Gram-positive bacteria and provide a platform for the development of a novel class of anti-infective agents.
“At this point, we have a chemical scaffold – a starting piece of the puzzle. We know that this piece is effective, and so right now all efforts are focused on evaluating the properties of these molecules and their in vivo efficacy,” says Pierce. “The hope is that we can build upon this scaffold to create drugs that are effective against MRSA and other resistant bacteria at a time of dire need for antimicrobial development while also increasing the spectrum of activity.”
The Latest on: Antimicrobial development
via Google News
The Latest on: Antimicrobial development
- GSK advances new antibiotic into Phase 3 studieson October 28, 2019 at 8:45 am
Traditional drug payment models, based on volume sold, have largely failed to support development of novel antibiotics — use of which is often limited in efforts by health authorities and physicians ...
- Government invests £3.5 million into development of new treatments for gonorrhoeaon October 28, 2019 at 7:34 am
The initiative will allow global access to treatment, including in low- and middle-income countries where the burden of antimicrobial resistance is highest and fund GARDP’s development of oral ...
- Curetis Group Company Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Teston October 28, 2019 at 2:31 am
Ares Genetics’ R&D programs for the development of ARESupa are co-funded by non-dilutive public grants provided ... cartridge-based solutions for the comprehensive and rapid detection of pathogens and ...
- Busy month for the world of antibiotics product developmenton October 27, 2019 at 9:14 pm
The activity comes against the backdrop of the completion of the U.S. government's Antimicrobial Resistance (AMR) Challenge, a yearlong effort to accelerate the fight against antimicrobial resistance ...
- Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: Pravibismaneon October 25, 2019 at 5:00 am
This dual antimicrobial action from this first-in-class microbial bioenergetic inhibitor ... among others, relating to the success of clinical development of pravibismane and preparation for potential ...
- Tracking Antimicrobial Resistance in the Sustainable Development Goalson October 22, 2019 at 11:12 am
In retrospect, it seems hardly possible that the Millennium Development Goals failed to mention tobacco control, but the Framework Convention on Tobacco Control helped ensure a much needed course ...
- Researchers Estimate Costs of Exclusivity Extensions to Encourage Antibiotic Developmenton October 21, 2019 at 2:01 pm
John Shimkus (R-IL), who is not seeking re-election, and co-sponsored by two Democrats, was calculated by identifying antimicrobial drugs approved ... has yet led to a measurable impact on drug ...
- Antimicrobial Coatings Market Size, Share will reach 7.5 Billion USD by the end of 2026on October 21, 2019 at 9:07 am
Antimicrobial coatings (AMC) are the paint formulations with biocides to improve ... Anti-Microbial Coatings Innovations (AMiCI) consortium is actively studying the regulation, development, and real ...
- Pharmacy experts on aggressive mode to devise strategies to tackle antimicrobial resistanceon October 20, 2019 at 7:30 pm
Multipronged and entirely new approach is required to minimize the emergence and spread of antimicrobial resistance. Greater innovation and investment are required in research and development of new ...
via Bing News